RYTM

+ Watchlist + Portfolio

Rhythm Pharmaceuticals, Inc.

Regulated industry Physical productsTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $92.83
52-Week Range: $74.50 – $122.20
Market Cap: $6.34B
P/E (TTM): —
EPS (TTM): -3.12
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 61.80
PEG Ratio: —
Return on Equity: -117.05%
Return on Assets: -30.96%
Gross Margin: 89.00%
Operating Margin: -68.14%
Profit Margin: -85.59%
Current Ratio: 3.45
Debt/Equity: 0.51
Total Debt: $109.78M
Free Cash Flow: $-130.59M
Revenue Growth: 46.90%
Earnings Growth: —
Enterprise Value: $6.26B

RYTM Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$23.64M	$77.43M	$130.13M	$189.76M
Cost of Revenue	$2.13M	$9.30M	$13.37M	$19.49M
Gross Profit	$21.50M	$68.13M	$116.76M	$170.26M
Research & Development	$108.63M	$134.95M	$237.96M	$167.34M
Selling, General & Admin	$92.03M	$117.53M	$144.30M	$194.94M
Operating Expenses	$200.66M	$252.48M	$382.26M	$362.28M
Operating Income	-$179.16M	-$184.36M	-$265.50M	-$192.02M
EBITDA	-$174.25M	-$168.46M	-$238.09M	-$174.12M
Pretax Income	-$181.12M	-$184.11M	-$260.26M	-$196.04M
Income Tax	$0.00	$564.00K	$346.00K	$497.00K
Net Income	-$181.12M	-$184.68M	-$260.60M	-$196.54M
Diluted EPS	-3.47	-3.20	-4.34	-3.11
Diluted Shares	52.12M	57.67M	61.00M	64.98M

RYTM Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$127.68M	$60.08M	$89.14M	$54.30M
Receivables	$6.22M	$14.87M	$18.51M	$26.08M
Inventory	$2.92M	$8.62M	$18.74M	$25.75M
Current Assets	$354.24M	$308.27M	$374.20M	$466.92M
Total Assets	$382.48M	$332.75M	$392.27M	$480.20M
Current Liabilities	$39.81M	$55.20M	$115.52M	$105.94M
Total Debt	$1.94M	$1.26M	$3.94M	$3.99M
Total Liabilities	$118.22M	$162.99M	$227.72M	$210.17M
Retained Earnings	-$710.06M	-$894.74M	-$1.16B	-$1.35B
Shareholders' Equity	$264.26M	$169.76M	$164.55M	$270.03M
Working Capital	$314.43M	$253.06M	$258.68M	$360.97M

RYTM Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$173.43M	-$136.16M	-$113.88M	-$115.67M
Capital Expenditure	-$4.28M	-$47.00K	—	-$953.00K
Free Cash Flow	-$177.71M	-$136.20M	-$113.88M	-$116.63M
Depreciation & Amortisation	$1.67M	$1.76M	$1.56M	$1.34M
Stock-Based Compensation	$19.83M	$32.55M	$39.68M	$66.82M
Investing Cash Flow	$28.03M	-$5.67M	-$48.17M	-$137.15M
Financing Cash Flow	$213.83M	$74.37M	$191.24M	$217.96M
Net Change in Cash	$68.43M	-$67.45M	$29.19M	-$34.87M

RYTM Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$32.70M	$48.50M	$51.30M	$57.25M	$60.11M	$71.25M
Cost of Revenue	$3.65M	$5.54M	$5.50M	$4.80M	$7.16M	$8.93M
Gross Profit	$29.06M	$42.96M	$45.80M	$52.45M	$52.95M	$62.32M
Research & Development	$36.97M	$42.31M	$46.03M	$42.03M	$41.73M	$43.43M
Selling, General & Admin	$39.09M	$45.95M	$52.42M	$57.48M	$63.59M	$67.45M
Operating Expenses	$76.06M	$88.25M	$98.45M	$99.51M	$105.32M	$110.88M
Operating Income	-$47.00M	-$45.30M	-$52.65M	-$47.06M	-$52.36M	-$48.55M
EBITDA	-$43.63M	-$40.10M	-$47.75M	-$42.65M	-$50.26M	-$44.06M
Pretax Income	-$49.42M	-$46.30M	-$52.79M	-$47.54M	-$55.09M	-$48.85M
Income Tax	$80.00K	$337.00K	$111.00K	-$31.00K	$545.00K	$444.00K
Net Income	-$49.50M	-$46.63M	-$52.90M	-$47.51M	-$55.64M	-$49.30M
Diluted EPS	-0.81	-0.75	-0.82	-0.73	-0.83	-0.73
Diluted Shares	63.06M	63.68M	66.26M	66.88M	67.97M	68.59M

RYTM Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$106.09M	$135.59M	$52.08M	$54.30M	$62.14M	$65.61M
Receivables	$17.82M	$26.12M	$33.03M	$26.08M	$34.19M	$40.41M
Inventory	$19.32M	$18.87M	$22.11M	$25.75M	$28.65M	$30.52M
Current Assets	$369.29M	$360.68M	$494.80M	$466.92M	$430.09M	$426.56M
Total Assets	$386.69M	$372.73M	$506.87M	$480.20M	$442.32M	$437.27M
Current Liabilities	$111.82M	$129.46M	$104.27M	$105.94M	$103.20M	$123.59M
Total Debt	$4.06M	$4.19M	$4.14M	$3.99M	$3.84M	$3.68M
Total Liabilities	$223.60M	$239.15M	$211.19M	$210.17M	$204.70M	$219.97M
Retained Earnings	-$1.20B	-$1.25B	-$1.30B	-$1.35B	-$1.41B	-$1.46B
Shareholders' Equity	$163.09M	$133.58M	$295.68M	$270.03M	$237.62M	$217.30M
Working Capital	$257.46M	$231.22M	$390.54M	$360.97M	$326.89M	$302.98M

RYTM Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$40.35M	-$23.31M	-$26.62M	-$25.39M	-$44.19M	-$9.15M
Free Cash Flow	-$40.35M	-$23.31M	-$26.62M	-$26.34M	-$44.19M	-$9.15M
Depreciation & Amortisation	$383.00K	$379.00K	$304.00K	$272.00K	$252.00K	$251.00K
Stock-Based Compensation	$12.86M	$15.88M	$18.81M	$19.27M	$23.10M	$26.06M
Investing Cash Flow	$24.81M	$54.03M	-$246.35M	$30.35M	$57.05M	$14.01M
Financing Cash Flow	$32.50M	-$889.00K	$189.30M	-$2.95M	-$5.40M	-$1.17M
Net Change in Cash	$16.96M	$29.83M	-$83.67M	$2.01M	$7.47M	$3.70M

Market Snapshot

About

Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare genetic disorders of obesity. The company markets setmelanotide, an FDA-approved melanocortin-4 receptor agonist for treating rare diseases caused by impaired MC4R pathway signaling. Rhythm is advancing a pipeline of peptide therapeutics targeting genetic obesity and related metabolic disorders.